Ganymed


Also found in: Dictionary, Thesaurus.
Related to Ganymed: Ganymede

Ganymed

(religion, spiritualism, and occult)

Ganymed is asteroid 1,036 (the 1,036th asteroid to be discovered, on October 23, 1924). It is approximately 40 kilometers in diameter and has an orbital period of 4.3 years. It was named after the youth who was kidnapped to become the cupbearer of Zeus. Jacob Schwartz gives the astrological significance of this asteroid as “beautiful and attractive to both genders, the mortal becoming divine by surrendering to the divine.” According to J. Lee Lehman, “the asteroid Ganymed shows how we are able to submit ourselves to that which is beyond our personal power. In negative form, it is the way we evade even the awareness that there is anything beyond our own powers.”

Sources:

Kowal, Charles T. Asteroids: Their Nature and Utilization. Chichester, West Sussex, UK: Ellis Horwood Limited, 1988.
Lehman, J. Lee. The Ultimate Asteroid Book. West Chester, PA: Whitford Press, 1988.
Schwartz, Jacob. Asteroid Name Encyclopedia. St. Paul, MN: Llewellyn Publications, 1995.
References in periodicals archive ?
After the majority of 21 patients treated in a phase IIa trial showed a significant slow-down of the cancer, Ganymed has now recruited 210 patients for a phase IIb trial.
Helmut Schmidt, founder and president of GANYMED Computer GmbH, said, "By combining our local presence and experience with NMS' advanced communications products, our customers in Central Europe and Italy will benefit from fast response times, high-quality personal consulting, and the best solutions for today's voice, video, and data communications.
GANYMED Computer GmbH is an embedded distributor and system integrator of high-quality, professional computer, network and communications solutions.
GENEVA, Switzerland, July 11 /PRNewswire-FirstCall/ -- Selexis SA, a Swiss-based biotechnology company offering technologies and services to enable significantly improved drug discovery, development, and cGMP production, announced today that it has signed a commercial license agreement with GANYMED Pharmaceuticals AG, a privately held cancer antibody company of Mainz, Germany, for use of the Selexis technology for large scale production of GANYMED's lead antibodies.
This commercial license agreement allows GANYMED to use a high performance cell line, developed by GANYMED scientists using the Selexis SURE Cell Line Development platform, for the clinical and commercial production of a number of products.
We are thrilled to be extending and possibly intensifying our relationship with GANYMED Pharmaceuticals.
Genmab acquired a license for Ganymed Pharmaceuticals AG's cancer target GT43.
COPENHAGEN, Denmark, April 26 /PRNewswire/ -- Genmab A/S (CSE: GEN) and privately held Ganymed Pharmaceuticals AG located in Germany, announced today that Genmab will license Ganymed's GT43 cancer target.
Under the terms of the agreement, Ganymed will be entitled to license fees, milestones and royalties on the sale of successfully commercialised products.
Companies contributing included: Antisoma, AstraZeneca, Baxter, Biogen, Boehringer Ingelheim, Celltech, Galileo Pharmaceutical, Ganymed Pharmaceuticals, GlaxoSmithKline, Hoffman-La Roche, Lundbeck, Novartis, Novo Nordisk, Orion, Pfizer, Proctor & Gamble, and Schering.